Abstract. The aim of the present study was to compare the efficacy and safety of fosfomycin combinational therapy with other antibiotics for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). This retrospective cohort study examined 104 cases of sepsis caused by CRKP occurring between January 2012 and November 2014 in Shanghai Tenth People's Hospital. Three categories of patient outcome were assessed: Survival/mortality, duration of intensive care unit stays and duration of medical ventilation. Univariate ordinal analyses were adopted to evaluate the correlations between outcome and treatment. A total of 104 patients with physician-diagnosed CRKP were involved in the study. The overall mortality rate was 25.0%. The majority of the infections (84; 80.8%) were hospital acquired. Critical infections received more than one active antibiotic as therapy. Patients treated with fosfomycin combinational therapy were less likely to fail therapy (OR: 4.71, 95% CI: 1.03-21.65, P=0.034) and tended to have a shorter duration of mechanical ventilation. Gender (OR: 4.35, 95% CI: 1.08-3.60, P= 0.037), history of chronic obstructive pulmonary disease (OR: 9.35, 95% CI: 0.06-0.19, P=0.007) and peripheral catheter use (OR: 3.00, 95% CI: 0.07-0.19, P=0.002) are risk factors for clinical outcome. Therefore, the use of fosfomycin combinational therapy for treatment of infection due to CRKP appears to be associated with improved survival rate.
Introduction
I n f e c t i o n s c a u s e d b y c a r b a p e n e m -r e s i s t a n t Klebsiella pneumoniae (CRKP) have been a serious problem due to limited therapeutic options all around the world (1) . Few optimal therapy strategy are available for the infections, making its treatments extremely difficult and leading to poor therapeutic outcomes with the reported mortality rates ranging from 39-72% (2-4). The core issue of managing CRKP infection is to find an effective antibiotic regimen, as carbapenem resistance is often accompanied by resistance to other families of first-line antibiotics, such as beta-lactam inhibitors, quinolones and 3rd/4th generation cephalosporin. Optional antibiotics are usually limited to polymyxins, aminoglycosides, gentamicin, colistin and tigecycline (5, 6) .
Recently, a study reported that treatment with tigecycline or an aminoglycoside can generate positive outcomes (7) . In addition, there are reports indicating that the use of carbapenems in combination with other active agents could contribute to a lower mortality, particularly when the strains have low levels of in vitro resistance to those antimicrobials (8) . Furthermore, a number of reports suggest that combinational therapies are often more effective than monotherapies (9, 10) . Therefore, the goal of this retrospective study was to analyze the effect of combinational therapy of fosfomycin and carbapenemase on mortality from sepsis due to CRKP.
Patients and methods
Patients. The retrospective study was conducted in a teaching hospital of Tongji University (Shanghai, China). From January 2012 to November 2014. All CRKP isolates were collected from the database of the Microbiology Service of the Shanghai Tenth People's Hospital of Tongji University. The clinical records of patients with CRKP isolates were reviewed. The enrollment criteria were as follows: i) Clinical evidence of sepsis, severe sepsis or septic shock due to CRKP; ii) meropenem or imipenem were used within 72 h after CRKP cultured from urine, blood, phlegm or drainage liquid; iii) the administration of meropenem therapy lasted for at least 72 h; and iv) >18 years old.
Admission to intensive care unit (ICU) was defined as a stay of 24 h before or after diagnosis of the severe sepsis. However, no difference between length of ICU stays and duration of mechanical ventilation was observed in these two groups (Table I ). The primary characteristics of the patients who received fosfomycin combinational therapy are shown in Table IV . According to the result, the number of patients that underwent prior use of minoglycosides and carbapenems differed between the two groups. Compared with other regimens (10.2±11.0 vs. 13.0±11.2), fosfomycin combination group tends to have shorter duration of mechanical ventilation, however the difference did not display statistical significance. An interesting thing is that the age of fosfomycin combinational therapy group is older than other treatments group (68.7±14.6 vs. 62.0±18.3, P= 0.065), which might give us a hint that fosfomycin combinational therapy is safer and more suitable to be applicable to aged people. The fosfomycin combinational therapy group has an overall mortality of 8.3% with one case died of pneumonia and another died of the infection of the central nervous system (Table V) .
Taking the difference in prior use of aminoglycosides into consideration, the effect of fosfomycin in combination with meropenem and with other regimens treatment was compared (Table VI) . This combinational therapy group has 16 patients. Compared with other therapy, a significant difference was observed (Table VI, P=0 .010) when compared with treatment by using 3rd/4th generation (monotherapy or combinational therapy).
Risk factors for mortality. Differences between cases of mortality and survival was observed using univariate analysis (Table I) . Peripheral catheter and history of COPD have a negative influence on survival rates (P= 0.01 and P= 0.016). Meanwhile, compared with female patients, male patients have a higher mortality. Fosfomycin combinational therapy (7.7 vs. 24.6%) was associated with lower mortality (Table I) The survival analysis performed using Kaplan-Meier curves showed that patients treated with fosfomycin combinational therapy had higher survival rates at 45 days after diagnosis (Fig. 1 , log-rank test t=3.96, P=0.047). However, in a multivariate analysis, no correlation between fosfomycin combination and outcome was observed (Table VII, P=0.141).
Discussion
CRKP has become a major hospital pathogen worldwide, and infections due to this organism have been associated with high mortality (9, (11) (12) (13) . The increasing prevalence and the high mortality associated with the organism underscore the importance of effective antimicrobial therapy for these serious infections. However, optimal treatment for infections caused by CRKP has not yet been defined (14) . The present retrospective study involved 104 unique patients with bacteremia due to CRKP with overall mortality rate of 25%, which is substantially lower than the rates reported for CRKP in previous studies (11, 15, 16) . Alternatively, the difference may be resulted from unrecognized confounding variables. Nonetheless, the mortality still remains considerably higher than for bacteremia due to CRKP (17) .
We identified gender, peripheral catheter and history of COPD as independent clinical risk factors for mortality. The present study demonstrated that survival in patients with CRKP was significantly improved when combinational therapy rather than monotherapy was administered. Fosfomycin combinational therapy is successful in the present study compared with other monotherapy and combination regimens. Alternatively, as monotherapy, fosfomycin could drive resistance develops rapidly (18) . In the present study, no patients were included that received fosfomycin monotherapy. Fosfomycin is a broad spectrum antibiotic that inhibits peptidoglycan synthesis (19) . Fosfomycin inhibits bacterial cell wall biogenesis by inactivating the enzyme UDP-N-acetylglucosamine-3-enolpyruvyltransferase which is also known as MurA (20) . This enzyme is able to catalyze the committed step in peptidoglycan biosynthesis, namely the ligation of phosphoenol pyruvate to the 3'-hydroxyl group of UDP-N-acetyl glucosamine (20) , which may provide a route for meropenem to enter the bacteria. It can be administered in combination with some other antimicrobial agents, since there is low level of or no cross resistance (21) . This agent is well tolerated and has a few side effects. It has an increased role as a therapeutic option against multidrug-resistant Enterobacteriaceae (19, 20, 22, 23) . Cumulative susceptibility of fosfomycin against ESBL positive Enterobacteriaceae is reported as 87.7% according to CLSI criteria (24) . However, lower susceptibility rates (<50%) was showed in some studies, and in a study this agent was shown to be active against only 50% of Klebsiella (22, 25) .
Qureshi et al (3) reported that either colistin-polymyxin B or tigecycline in combination with a carbapenem appeared to be effective. These combination regimens were more successful than monotherapy with either colistin-polymyxin B or tigecycline, even when in vitro testing confirmed susceptibility to the respective antimicrobials. While the mechanisms underlying the effectiveness of these combinations are not known, synergistic activity between carbapenems and colistin has been observed in vitro among their CRKP isolates, which is consistent with the clinical observation, at least for this particular combination. It is considered that treatment with fosfomycin is free from the nephrotoxicity that characterizes treatment with aminoglycosides. A previous animal study demonstrated that fosfomycin has a protective effect against nephrotoxicity as a result of treatment with aminoglycosides by inhibiting aminoglycoside-induced histamine release from mast-cell destruction (26) .
The present study is limited by its observational nature and relatively small number of cases, since we limited the analysis to cases with bacteremia only. In conclusion, mortality associ- ated with bacteremia due to CRKP continues to be high. The use of combinational therapy, with fosfomycin combinational therapy in particular, seems to have a survival benefit in this critically ill population. 
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